Silmitasertib

Silmitasertib (CX-4945), a CK2 inhibitor, shows anticancer activity in various tumors and is being tested in early human trials for cholangiocarcinoma, basal cell carcinoma, medulloblastoma, and neuroblastoma. It enhances anticancer activity when combined with DNA-damaging chemotherapy drugs and is also being tested for severe Covid-19 symptoms, reducing cytokine storm and improving recovery times.

Senhwa Biosciences enrolls first subject in Phase I/II trial at Penn State Health Children’s Hospital to evaluate silmitasertib (CX-4945) with chemotherapy for relapsed or refractory solid tumours in children and young adults. The trial aims to establish a recommended dosage, assess tolerability, safety, and efficacy, particularly for neuroblastoma and sarcomas. Expected to enroll up to 114 individuals via Beat Childhood Cancer Research Consortium member hospitals, the study is supported by the Beat Childhood Cancer Foundation and the Little Warrior Foundation.

Senhwa Biosciences enrolls first patient in Phase I/II study of Silmitasertib combined with chemotherapy for relapsed or refractory solid tumors in children and young adults, aiming to establish a recommended dose and assess safety, tolerability, and efficacy, with a focus on neuroblastoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma.

Penn State College of Medicine, Beat Childhood Cancer Research Consortium, Four Diamonds, and Senhwa Biosciences launch a clinical trial evaluating the investigational drug silmitasertib in combination with FDA-approved drugs for solid tumors in children and young adults, focusing on neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma. The trial aims to establish a recommended dose, assess safety, tolerability, and efficacy, and enroll up to 114 participants nationwide. Funding is provided by the Beat Childhood Cancer Foundation and the Little Warrior Foundation.

Penn State College of Medicine, Beat Childhood Cancer Research Consortium, and Four Diamonds launch a clinical trial to evaluate silmitasertib in combination with FDA-approved drugs for solid tumors in children and young adults, focusing on neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma.